^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 modulator

    Related drugs:
    7d
    KEYNOTE-B59: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=317, Recruiting, GI Innovation, Inc. | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Oct 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)
    1m
    ACT18053: A study to investigate the efficacy and safety of SAR444336 in adults with microscopic colitis in clinical nremission. (2024-519495-83-00)
    P1/2, N=78, Recruiting, Sanofi-Aventis Recherche & Developpement
    New P1/2 trial
    4ms
    A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission (clinicaltrials.gov)
    P2, N=54, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    ALSTARS: Study of COYA 302 for the Treatment of ALS (clinicaltrials.gov)
    P2, N=120, Recruiting, Coya Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    7ms
    ALSTARS: Study of COYA 302 for the Treatment of ALS (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Coya Therapeutics
    New P2 trial
    7ms
    A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Sanofi
    New P2 trial
    10ms
    DEKA-1: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, DEKA Biosciences | Recruiting --> Active, not recruiting | N=60 --> 39 | Trial primary completion date: Mar 2025 --> Jul 2025
    Enrollment closed • Enrollment change • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    EGFR expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)
    10ms
    The effect of an intravenous analgesic pump with esketamine on postoperative pain and postpartum depression in women with cesarean section. (PubMed, Am J Transl Res)
    Esketamine-based postoperative analgesia for cesarean section effectively reduces perioperative pain, alleviates postpartum depression, mitigates inflammatory and stress responses, and has certain neuroprotective effects. Its safety profile supports its potential for broader clinical use.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BDNF (Brain Derived Neurotrophic Factor)
    1year
    Xiapyrroles A-F: N-Alkylpyrrole Alkaloids from the Marine-Derived Actinomycete Streptomyces xiamenensis 1310KO-148. (PubMed, J Nat Prod)
    However, 1 dose-dependently suppressed the LPS-induced production of NO (IC50 = 29.5 μM) and interleukin-6 (IL-6) (IC50 = 10.9 μM). Compound 1 exhibited no potential cytotoxicity against six solid cancer cell lines and eight blood cancer cell lines at a concentration of 30 μM.
    Journal
    |
    IL6 (Interleukin 6)
    1year
    DEKA-1: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, DEKA Biosciences | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    EGFR expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)
    over1year
    A Single-Center, Phase II, Randomized, Controlled Clinical Study Evaluating Injectable Thymofaxine (Nitazan) in Combination with Injectable Human Interleukin-2 (Deruson) for the Treatment of Lymphopenia in Patients with Malignant Hematologic Neoplasms (ChiCTR2400090033)
    P2, N=45, Not yet recruiting, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New P2 trial • Combination therapy
    |
    CD4 (CD4 Molecule)
    over1year
    First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Egle Therapeutics
    New P1/2 trial